Bruker (BRKR) to Release Quarterly Earnings on Thursday

Bruker (NASDAQ:BRKR) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Bruker to post earnings of $0.65 per share and revenue of $964.6130 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Bruker Stock Up 0.4%

Shares of NASDAQ:BRKR opened at $42.10 on Tuesday. The firm has a market capitalization of $6.40 billion, a PE ratio of -263.13, a price-to-earnings-growth ratio of 5.51 and a beta of 1.19. The business has a 50 day simple moving average of $47.59 and a two-hundred day simple moving average of $40.56. Bruker has a 1 year low of $28.53 and a 1 year high of $56.22. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $6,319,395.60. This represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 27.30% of the company’s stock.

Institutional Trading of Bruker

Hedge funds have recently bought and sold shares of the stock. Allworth Financial LP increased its holdings in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. EverSource Wealth Advisors LLC boosted its position in Bruker by 51.5% during the second quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 942 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Bruker by 56.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 1,497 shares during the last quarter. Twin Tree Management LP grew its stake in Bruker by 195.0% in the third quarter. Twin Tree Management LP now owns 5,616 shares of the medical research company’s stock valued at $182,000 after purchasing an additional 11,528 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in Bruker in the second quarter worth about $217,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Monday, December 29th. Barclays boosted their target price on shares of Bruker from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research note on Wednesday, December 10th. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Finally, Citigroup upped their target price on shares of Bruker from $40.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Bruker has a consensus rating of “Hold” and an average price target of $53.23.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.